drugset / Trial / NCT00307619

An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder.

NCT00307619 ↗

Phase 3 Completed 73 enrolled Janssen-Cilag Farmaceutica Ltda.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness and tolerability of topiramate compared to placebo in patients with binge eating disorder receiving Cognitive Behavior Therapy (CBT)

Timeline

Start
2003-11
Primary completion
—
Completion
2005-04

Outcome

Met primary endpoint

paper Repeated-measures random regression analysis revealed a greater rate of weight reduction associated with topiramate over the course of treatment (p < .001) PMID 17915969 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Topiramate Small molecule 200 mg —

Indications